R. H. Joseph Shaw, Chief Executive Officer and Chairperson, Syntiron
Mr. Shaw has over 20 years experience in the development and commercialization of biotechnology innovations. He has extensive experience in strategic collaborating and raising funds from both public and private sources. Mr. Shaw's direct international experience includes Canada, Europe, South East Asia, China, and Japan. Previously Mr. Shaw served as CEO of OpGen Inc., a nanotechnology genomics company based in Wisconsin. Prior to this, he was interim President of Bank on a Cure, a global study project of the International Myeloma Foundation, the first comprehensive myeloma-specific cancer patient DNA bank. During his tenure, Mr. Shaw worked to coordinate and develop a fully functioning enterprise, combining multiple institutions and patient support groups. Simultaneously, he served as President of AusAmerican Group, Inc.'s North America division. AusAmerican Group Inc. is a consulting firm that provides a full range of business services to Australian and American corporations, from medical group practices to start-up biotechnology companies seeking to introduce products or services into the Australian or U.S. marketplace. From 1999 to 2004, Mr. Shaw was Managing Director and CEO of Ambri Limited, Inc., the medical division of Pacific Dunlop Limited, an Australian conglomerate. Ambri develops nanotechnology and biotechnology diagnostic devices. Under his leadership, Ambri listed on the Australian stock exchange, raising more than $32 million. At the time, this was the largest biotechnology listing in Australia to date. He also negotiated strategic investments from Dow Corning and Genencor, Inc. Previously he served as CEO and Chairperson of the Board of Quantech Inc., a biosensor technology company, and CEO of Cathra International, a bacteriological testing company. He has held senior executive positions with KVet/KVL Limited, a human and veterinarian medical company, QuadraLogics, which specializes in cancer therapeutics and Johnson & Johnson. In 2002 and 2003, Mr. Shaw spoke at the Australian/American Leadership Conference conducted at the White House. He also participated as a speaker at the Commonwealth Government's Australian Development Congress in 1999, 2000, 2001 and was a member of the "Prime Minister's Science Council" of Australia. He has been a frequent guest speaker at both U.S. and international government and academic forums regarding the development and commercialization of biotechnology innovations.

Lee Byberg, VP of Operations, Life Science Innovations
Mr. Byberg earned his MBA and BA from the University of Minnesota and has over 15 years of U.S. and international business experience as a consultant through Coopers & Lybrand and an economic evaluator for Phillips Petroleum Company in Norway. Currently, Mr. Byberg is the General Manager for Willmar Poultry Company.

Daryll A. Emery, M. Sc., Ph. D., Chief Science Officer, Epitōpix
Dr. Emery joined Willmar Poultry in 1991. Dr. Emery developed, patented, and implemented the SRP vaccine technology along with Darren Straub (of Epitōpix). Prior to joining Willmar Poultry, Dr. Emery was a scientist at the University of Minnesota, focusing on the pathogenesis of bacterial and viral diseases in turkeys and chickens. Dr. Emery has published numerous papers on his research and has been involved in the development of over 30 patents. He received a Ph.D. in Veterinary Microbiology/Immunology and an M.S. in Microbiology/Poultry Science from the University of Minnesota, College of Veterinary Medicine, and Department of Avian Diseases in Minnesota. Dr. Emery received a B.S. in Biology/Community Health from Mankato State University, also in Minnesota.

James Sandstrom, DVM, General Manager, Epitōpix
Dr. Sandstrom has been the General Manager of Epitōpix since March 2002. Prior to that, Dr. Sandstrom was Manager of the Swine Business Unit at Intervet, Inc. From 1998 to 2000, Dr. Sandstrom was Manager of Technical Marketing / Global Feed Additives at Hoechst Roussel Vet in Wiesbaden, Germany. From 1997 to 1998, Dr. Sandstrom was Vice President of Sales &

Marketing at Nicholas Turkey Breeding Farms in California. From 1990 to 1997, Dr. Sandstrom was a Technical Service Veterinarian at Hoechst Roussel Agri-Vet in New Jersey. Dr. Sandstrom is a member of the American Veterinary Medical Association, the American Association of Avian Pathologists, the American Association of Swine Practitioners, and the American Association of Bovine Practitioners, and is board certified by the American College of Poultry Veterinarians. Dr. Sandstrom received a Doctor of Veterinary Medicine from the University of Minnesota College of Veterinary Medicine in St. Paul, Minnesota.

Vivek Kapur, B.V.Sc, Ph. D., Professor of Microbiology and Infectious Diseases, Penn State
Dr. Kapur is Professor and Head of the Department of Veterinary and Biomedical Sciences at Penn State, and a co-founder of Syntiron. Prior to his appointment at Penn State in 2007, Professor Kapur served on the faculty at the University of Minnesota since 1995 with primary appointments in the Medical School and College of Veterinary Medicine was Director of the Biomedical Genomics Center with overall responsibility for directing the genetic and genomics research and core service laboratories at the University. Prof. Kapur received his training in Veterinary Medicine from the University of Agricultural Sciences in Bangalore, India and a Ph.D. in Veterinary Science from Penn State in 1991. From 1992 to 1995, he was a postdoctoral research associate and junior faculty member at Baylor College of Medicine in Houston, Texas, where he worked on understanding the molecular mechanisms by which human and animal pathogens cause disease. His current research focuses on using genomics-based approaches to elucidate the basic mechanisms by which microbes cause disease and the host responds to infection, including the role of iron. Prof. Kapur is the recipient of numerous awards and honors, including the Rotary Foundation Freedom from Hunger Award, the Pfizer Award for Research Excellence, the Merck AgVet Award for Teaching, the Schofield Medal, and the 2008 Pasteur Award. Prof. Kapur has also chaired and served on numerous study sections including those for NIH and the USDA, and is an elected member of the prestigious Faculty of 1000.

Lisa Herron-Olson, Ph. D., Senior Scientific Director, Syntiron
Dr. Herron-Olson has eight years of experience working in staphylococcal pathogenesis. After joining Syntiron in 2005, she initiated a program-to investigate the mechanism of vaccine protection by iron-regulated surface proteins derived from Staphylococcus aureus. Her early work focused on establishing defined antigen production protocols for S. aureus and identifying the roles of individual antigens in stimulating an immune response. Initial data resulted in the award of two Small Business Innovative Research grants from the NIH to study both the vaccine antigens and the resulting antibodies for prophylactic and therapeutic applications. Dr. Herron-Olson is an inventor on the current Gram-positive patent applications and has also served as the Principal Investigator on two NIH Phase I grants to study the development of vaccines to prevent both Salmonella and Yersinia. She became the Senior Scientific Director at Syntiron in 2007. In April of that year, Dr. Herron-Olson was awarded the Early Career Investigator Award at the Tenth Annual Conference on Vaccine Research. Prior to joining Syntiron, she conducted her undergraduate training in Biology at Kalamazoo College and the Universidad San Francisco de Quito in Cumbaya, Ecuador as a National Merit Scholar. Her studies in Ecuador led to an interest in infectious disease microbiology, and she subsequently earned her Ph.D. in molecular microbiology and bioinformatics in the laboratory of Dr. Vivek Kapur at the University of Minnesota. Her studies were supported by a fellowship from the NIH, as well as a Graduate School Fellowship for Biomedical Sciences. In the laboratory, she determined the complete genomic sequences of two isolates of Staphylococcus aureus and conducted a comparative genomic analysis that included functional comparison of the iron metabolic systems among S. aureus isolates from different hosts. Her work has been published in peer-reviewed journals, including Infection and Immunity and PLoS ONE, and she has presented her work with S. aureus and the SRP vaccines at several national and international meetings.